Johnson & Johnson NYSE:JNJ Price, Chart, News & Insight

Johnson & Johnson (NYSE: JNJ) gained 3.5% on Friday after receiving fresh analyst support, helping extend the stock's recent strength.

Johnson Rice initiated coverage with a $270 price target, while Guggenheim raised its price target to $270 from $266 and maintained its Buy rating. The updated analyst views reflect confidence in the company's diversified healthcare business, resilient pharmaceutical portfolio, and improving growth outlook.

Analysts continue to view Johnson & Johnson as well positioned to benefit from steady demand for its innovative medicines, expanding medtech business, and strong cash generation. The company is also expected to maintain its defensive appeal amid ongoing macroeconomic uncertainty.

The positive analyst actions reinforced investor sentiment, supporting gains in Johnson & Johnson shares as healthcare stocks attracted renewed interest.

💬 🔗

Global Finance News 06-26-26

Johnson & Johnson announced that the U.S. Food and Drug Administration has granted Priority Review to its drug IMAAVY (nipocalimab) for the treatment of warm autoimmune hemolytic anemia (wAIHA), a rare and life-threatening blood disorder.

Priority Review shortens the FDA evaluation timeline to around six months and is reserved for therapies that may offer significant improvements over existing options. Notably, IMAAVY is the first treatment to receive this designation for wAIHA, where no approved therapies currently exist.

Source: PRNewswire

💬 🔗

The Investor 04-27-26

Johnson & Johnson reported new long-term data showing that its investigational therapy IMAAVY (nipocalimab) delivered sustained disease control in patients with generalized myasthenia gravis (gMG) for over two years. Results from the Phase 3 Vivacity-MG3 study and its extension phase demonstrated continued improvements in symptoms, muscle strength, and quality of life, along with significant reductions in harmful IgG antibodies.

The data also indicated that patients achieving sustained minimal symptom expression experienced greater quality-of-life benefits, while many were able to reduce corticosteroid use. In parallel, Johnson & Johnson confirmed that its head-to-head EPIC study comparing IMAAVY with another FcRn blocker is now enrolling participants.

Source: PR Newswire

💬 🔗

Global Finance News 04-24-26

Johnson & Johnson unveiled new advancements in its electrophysiology portfolio at the Heart Rhythm Society (HRS) 2026 meeting, including the launch of the AI-powered CARTOSOUND SONATA module. The new technology enhances cardiac imaging and mapping by automatically converting intracardiac ultrasound data into detailed heart models, improving precision in treating arrhythmias.

The innovation integrates with existing CARTO systems and supports procedures for conditions such as atrial fibrillation and ventricular tachycardia. The company also presented new clinical data on its VARIPULSE platform, highlighting improved safety, efficiency, and real-world patient outcomes in pulsed field ablation therapies.

Marking 30 years of the CARTO system, Johnson & Johnson emphasized its continued focus on AI-driven innovation to advance cardiac care and improve treatment outcomes for heart rhythm disorders.
Business Wire

💬 🔗

European Investor 04-21-26

Johnson & Johnson (NYSE: JNJ) announced a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share.

The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on May 26, 2026. The ex-dividend date is May 26, 2026.

💬 🔗

WS Investor 04-14-26

Johnson & Johnson presented new clinical data for its TECNIS PureSee intraocular lens (IOL) at the 2026 ASCRS Annual Meeting, highlighting strong visual performance and patient outcomes.

Results from multiple studies across the U.S., Europe, and Asia-Pacific showed the lens delivers excellent distance and intermediate vision, high contrast sensitivity, and low levels of visual disturbances, alongside high patient satisfaction and reduced dependence on glasses.

The findings reinforce the product’s positioning as a next-generation extended depth-of-focus lens, supporting Johnson & Johnson’s strategy to advance innovation in vision care and improve surgical outcomes for cataract patients.
Business Wire

💬 🔗

European Investor 04-11-26

Johnson & Johnson announced the European launch of its VARIPULSE Pro platform following CE Mark approval, advancing its pulsed field ablation (PFA) technology for treating cardiac arrhythmias.

The new system features an improved pulse sequence that enables procedures up to five times faster while maintaining precision and safety. It integrates with the CARTO 3 mapping system to support accurate lesion delivery during treatment of conditions such as atrial fibrillation.

The company said the launch reflects ongoing innovation in minimally invasive cardiovascular therapies, with clinical data continuing to be generated through ongoing studies.

VARIPULSE Pro will be showcased at the European Heart Rhythm Association (EHRA) 2026 meeting as part of Johnson & Johnson’s broader push to enhance treatment outcomes in cardiac care.
Business Wire

💬 🔗

WS Investor 04-07-26

Johnson & Johnson announced that its bladder cancer therapy INLEXZO (gemcitabine intravesical system) has been assigned a permanent billing code in the United States, supporting broader patient access.

The Centers for Medicare & Medicaid Services granted the HCPCS J-code (J9183), effective April 1, enabling standardized reimbursement processes for eligible patients with certain types of non-muscle invasive bladder cancer. The update is expected to simplify administrative procedures for healthcare providers and improve treatment accessibility.

INLEXZO, approved by the FDA in 2025, is the first intravesical drug-releasing system designed to deliver cancer medication directly into the bladder over time, offering an alternative for patients with limited treatment options.

The company said the permanent coding designation represents a key step in reducing access barriers and facilitating more consistent use of the therapy in clinical practice.

💬 🔗

Global Finance News 04-03-26

Johnson & Johnson announced that the U.S. FDA has approved ICOTYDE (icotrokinra), a first-in-class oral IL-23 receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in patients aged 12 and older . The drug is the first targeted oral peptide in its class, offering a once-daily systemic treatment option.

The approval is based on Phase 3 data showing strong efficacy and safety, with around 70% of patients achieving clear or nearly clear skin and more than half reaching significant disease reduction (PASI 90) at 16 weeks. Safety results were comparable to placebo, with no new safety concerns identified.

The launch positions ICOTYDE as a potential first-line systemic therapy, addressing unmet needs for patients who do not respond adequately to topical treatments and marking a shift toward more convenient, oral-based treatment approaches in psoriasis care.
PRNewswire

💬 🔗

Global Finance News 03-19-26

Johnson & Johnson reported promising early clinical results for its investigational bladder cancer therapy Erda-iDRS, a drug-releasing system delivering erdafitinib directly into the bladder.

In a Phase 1 study involving patients with intermediate-risk non-muscle-invasive bladder cancer, the treatment achieved an 89% complete response rate, with many responses lasting up to 18 months. The therapy also showed encouraging recurrence-free outcomes in high-risk patients and demonstrated a generally tolerable safety profile.

The results, presented at the European Association of Urology 2026 meeting, support further development of the targeted therapy, with ongoing Phase 2 and Phase 3 trials evaluating its potential as a treatment option for early-stage bladder cancer.
PRNewswire

💬 🔗

The Investor 03-13-26

NYSE:JNJFollow

NYSE:JNJ